BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Röth A, Bommer M, Hüttmann A, Herich-Terhürne D, Kuklik N, Rekowski J, Lenz V, Schrezenmeier H, Dührsen U. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv 2018;2:2543-9. [PMID: 30291112 DOI: 10.1182/bloodadvances.2018024190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bylsma LC, Gulbech Ording A, Rosenthal A, Öztürk B, Fryzek JP, Arias JM, Röth A, Berentsen S. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv 2019;3:2980-5. [PMID: 31648316 DOI: 10.1182/bloodadvances.2019000476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
3 Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, Rosenthal A. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost 2020;4:628-35. [PMID: 32548562 DOI: 10.1002/rth2.12333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Herbreteau L, Le Calloch R, Arnaud B, Cassou N, Rizcallah MJ, Hutin P, Le Clech L. Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders. Ann Hematol 2021;100:2105-6. [PMID: 34003325 DOI: 10.1007/s00277-021-04557-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol 2021;8:e229-39. [PMID: 33636143 DOI: 10.1016/S2352-3026(20)30404-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev 2021;3:CD012493. [PMID: 33786812 DOI: 10.1002/14651858.CD012493.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Dawudi Y, Federici L, Debus J, Zucman N. Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab. BMJ Case Rep 2022;15:e242937. [PMID: 35487646 DOI: 10.1136/bcr-2021-242937] [Reference Citation Analysis]
8 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
9 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Anliker M, Schmidt CQ, Harder MJ, Ganchev G, von Zabern I, Höchsmann B, Schrezenmeier H, Weinstock C. Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. Transfusion 2018;58:2992-3002. [PMID: 30367826 DOI: 10.1111/trf.14893] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Garg M, Agarwal S, Altohami M. A single dose of eculizumab terminated life-threatening haemolysis in idiopathic IgM-mediated warm autoimmune haemolytic anaemia: A case report. Br J Haematol 2022. [PMID: 34993954 DOI: 10.1111/bjh.18011] [Reference Citation Analysis]
12 Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020;41:100648. [PMID: 31839434 DOI: 10.1016/j.blre.2019.100648] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis]
13 Alashkar F, Vance C, Herich-Terhürne D, Turki AT, Schmitz C, Bommer M, Hüttmann A, Dührsen U, Vogel U, Röth A. Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition. Vaccine 2019;37:6682-7. [PMID: 31562002 DOI: 10.1016/j.vaccine.2019.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
15 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and perspectives. Immun Ageing 2020;17:38. [PMID: 33292368 DOI: 10.1186/s12979-020-00208-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Berentsen S, Barcellini W, D'Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy 2022. [PMID: 35946351 DOI: 10.2217/imt-2022-0085] [Reference Citation Analysis]
18 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Reference Citation Analysis]
19 Pagano MB, Allen ES, Chou ST, Dunbar NM, Gniadek T, Goel R, Harm SK, Hopkins CK, Jacobson J, Lokhandwala PM, Metcalf RA, Raval JS, Schwartz J, Shan H, Spinella PC, Storch E, Cohn CS. Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee. Transfusion 2020;60:1614-23. [PMID: 32472580 DOI: 10.1111/trf.15848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Berentsen S. Cold agglutinins: fending off the attack. Blood 2019;133:885-6. [PMID: 30819775 DOI: 10.1182/blood-2019-01-894303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med 2019;10:93-103. [PMID: 31114413 DOI: 10.2147/JBM.S177621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
22 Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 2019;10:2040620719873321. [PMID: 31523413 DOI: 10.1177/2040620719873321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
23 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 2019;3:3575-8. [PMID: 31738828 DOI: 10.1182/bloodadvances.2019000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Gauchy AC, Hentzien M, Wynckel A, de Marcellus V, Rodier C, Delmer A, Quinquenel A. Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia. Clin Case Rep 2020;8:2641-4. [PMID: 33363796 DOI: 10.1002/ccr3.3250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019;133:893-901. [PMID: 30559259 DOI: 10.1182/blood-2018-06-856930] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
26 Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med 2019;10:265-78. [PMID: 31496855 DOI: 10.2147/JBM.S190327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
27 Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020;4:997-1005. [PMID: 32176765 DOI: 10.1182/bloodadvances.2019001321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
28 Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med 2020;9:E3859. [PMID: 33261023 DOI: 10.3390/jcm9123859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Autore F, Pasquale R, Innocenti I, Fresa A, Sora' F, Laurenti L. Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review. Cancers (Basel) 2021;13:5804. [PMID: 34830959 DOI: 10.3390/cancers13225804] [Reference Citation Analysis]
30 Gabbard AP, Booth GS. Cold Agglutinin Disease. Clin Hematol Int 2020;2:95-100. [PMID: 34595449 DOI: 10.2991/chi.k.200706.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Capecchi M, Ciavarella A, Artoni A, Abbattista M, Martinelli I. Thrombotic Complications in Patients with Immune-Mediated Hemolysis. J Clin Med 2021;10:1764. [PMID: 33919638 DOI: 10.3390/jcm10081764] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020;136:480-8. [PMID: 32374875 DOI: 10.1182/blood.2020005674] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]